Year: 2020
Type: article
Study design: Observational Study
Abstract: hematol transfus cell ther. 2 0 2 0;4 2(S 2):S1-S567 S283were associated with lower OS, while lenalidomide treatment was the only factor associated with its improvement.Multivariate analysis confirmed that ECOG ≥ 2 (HR 6.88 [CI95% 2.25 -21.09], p ≤ 0.001), > 2% of BM blasts (HR 3.66 [CI95% 1.09 -12.30], p = 0.04) and lenalidomide treatment (HR 0.31 [CI95% 0.12-0.80],p = 0.016) were associated with OS.Conclusion: Median OS of patients with isolated deletion 5q MDS seems slightly lower in this South American series when compared to previously published data.Some factors that can be easily assessed at diagnosis as performance status and the percentage of BM blasts are associated with to prognosis.And, the use of lenalidomide was associated with a better outcome, with a heterogeneity of access among patients due to the retrospective characteristic of the study.There is also a need to detect TP53 by detection by immunohistochemistry, molecular biology and FISH, which is not routinely available in South American centers.
Authors: B.M. Klauck, B. Silva, F.P. Rigon, L.F. Corbari, N.A. Hora, S.L. Utzig, M.A.F. Chaves
Institution: Universidade Estadual do Oeste do Paraná
Language: Portuguese
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3097970985